Compare FOXF & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOXF | FBRX |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 800.6M | 899.4M |
| IPO Year | 2013 | 2017 |
| Metric | FOXF | FBRX |
|---|---|---|
| Price | $18.75 | $76.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $30.25 | ★ $67.00 |
| AVG Volume (30 Days) | 466.9K | ★ 2.0M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,467,321,000.00 | $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.90 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.27 | N/A |
| 52 Week Low | $13.08 | $9.28 |
| 52 Week High | $30.75 | $77.20 |
| Indicator | FOXF | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.25 | 84.76 |
| Support Level | $17.39 | $24.72 |
| Resistance Level | $18.62 | N/A |
| Average True Range (ATR) | 0.93 | 3.60 |
| MACD | -0.01 | 2.10 |
| Stochastic Oscillator | 52.45 | 98.49 |
Fox Factory Holding Corp is a designer, manufacturer, and marketer of performance-defining products and systems used predominantly on bikes, Side-by-Sides, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. Its business operates under the FOX, FOX RACING SHOX, and RACE FACE brands. Geographically, it derives a majority of revenue from North America and also has a presence in Asia, Europe, and the Rest of the World. The company operates in three segments: Powered Vehicles Group, Aftermarket Applications Group, and Specialty Sports Group, of which it derives maximum revenue from Specialty Sports Group segment.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.